COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

Open label, multi-center, phase 1b/2 clinical trial to evaluate the safety and efficacy of autologous CAR-BCMA T cells (CT053) in patients with relapsed and/or refractory multiple myeloma

Protocol No
CARSGEN-CT053-MM-02
Principal Investigator
Binod Dhakal
Phase
I/II
Summary
This project is being done to see whether zevor-cel (CT053) can be used to treat others with your disease in the future.
Description
Clinical Trial to Evaluate CT053 in Patients with R/R-MM (LUMMICAR Study 2)
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL